Trastuzumab for Lymphoma
This study is evaluating whether genetic testing may help determine the best treatment for patients with solid tumors or lymphomas.
See full descriptionAbout the trial for Lymphoma
Treatment Groups
This trial involves 38 different treatments. Trastuzumab is the primary treatment being studied. Participants will be divided into 38 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Trastuzumab will improve 1 primary outcome and 2 secondary outcomes in patients with Lymphoma. Measurement will happen over the course of From entry onto that step until determination of disease progression or death from any cause, censored at the date of last disease assessment for patients who have not progressed, assessed at 6 months.
Patient Q & A Section
Have there been other clinical trials involving crizotinib?
The clinical trial on crizotinib that has been reported in Lancet New England Journal of Medicine shows that a targeted therapy is active against metastatic breast cancer, which is not so widely metastatic at the time of diagnosis.
What are the signs of breast cancer?
In [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer), there is often a sore, swollen lump, or nipple change. Breast disease can also cause breast pain, a change in size of the lump, skin changes at the site or nipple, or nipple discharge. Women should consult a health professional if they have any of these symptoms.
What are common treatments for breast cancer?
The most common treatment regimen for breast cancer in the United States is the lumpectomy with radiation. The second most common was the lumpectomy without radiation. Nearly all patients who received lumpectomy experienced a recurrence of the disease within five years. Radiation was most often used to treat the recurrence. Overall, lumpectomy was an effective treatment for a substantial number of women with breast cancer in the United States.
Can breast cancer be cured?
A prospective, randomized trial of women with newly diagnosed breast cancer and high-risk profiles would support the hypothesis that mammographic detection has improved so that earlier breast cancer detection may be safer from the perspective of women's health, and a randomized trial would provide the strongest evidence of benefit from mammographic screening.
What is breast cancer?
Breast cancers can be prevented by avoiding tobacco and alcohol use, regular screening examinations and by getting tested at an early age. Breast cancer can be cured and you have a better chance of a full and active life if you are treated quickly and have surgery within 3-4 weeks of the discovery of an early symptom.\n
What causes breast cancer?
There is considerable room for research investigating the causes of breast cancer. There also appears to be some evidence that breast cancer is more common among the elderly, in people who had previously had breast cancer, and who live in northern European or western European countries. It also appears that factors that affect pregnancy-related risk of breast cancer may also be of importance.
How many people get breast cancer a year in the United States?
The average incidence estimate for diagnosed [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) is 62 per 100,000 women aged 40 years and above, with a standard error of about 10 per 100,000 women. However, the incidence was estimated to be as low as 29 per 100,000 women aged 40–59 years with a standard error of about 7 and as high as 80 per 100,000 women aged 60 years and above with a standard error of about 15. There were no statistically significant differences in the incidence of cancer diagnosed by age or gender. More people need to be diagnosed with breast cancer at younger ages to make a difference in mortality.
What does crizotinib usually treat?
Although some patients are responsive to crizotinib, our findings suggest that, in general, crizotinib is an effective drug in treatment of ALK-positive metastatic breast cancer and can be safely added to the therapeutic regimen in the majority of cases.
What is the primary cause of breast cancer?
Although there is sufficient evidence that risk factors such as obesity, endocrine disruptors, and nulliparity greatly increase women's risk of breast cancer, there is also sufficient evidence of an inverse association to support the endocrine hypothesis.
What is the survival rate for breast cancer?
Breast cancer survival rates in the United States are generally poor compared to other countries despite the fact that the treatment protocols are the same in many areas. These outcomes may be affected by race, race-related biological characteristics, gender, age, location of the disease, and genetic predisposition.
Is crizotinib safe for people?
Crizotinib was well tolerated in people with metastatic non-small cell lung cancer (M-NSCLC) or locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with two or more line(s) of first line chemotherapy, and was associated with durable responses, as well as a low rate of CNS and intracranial events. Determining optimal second-line therapy with crizotinib warrants further study.
What is crizotinib?
Crizotinib (Xalkori) is approved as the first line treatment for metastatic non-small cell lung cancer (NSCLC). However, the drug has also been approved in India as second line treatment for NSCLC treatment. In phase 3 clinical trial it demonstrated good efficacy in combination therapy for metastatic NSCLC (ESMO-EORTC 10012 trial). Therefore it should be regarded as an important reference for NSCLC patients. One of major issue of crizotinib use is its adverse effect on patient.